1. Home
  2. EWTX vs OI Comparison

EWTX vs OI Comparison

Compare EWTX & OI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • EWTX
  • OI
  • Stock Information
  • Founded
  • EWTX 2017
  • OI 1903
  • Country
  • EWTX United States
  • OI United States
  • Employees
  • EWTX N/A
  • OI N/A
  • Industry
  • EWTX Biotechnology: Pharmaceutical Preparations
  • OI Containers/Packaging
  • Sector
  • EWTX Health Care
  • OI Consumer Discretionary
  • Exchange
  • EWTX Nasdaq
  • OI Nasdaq
  • Market Cap
  • EWTX 1.6B
  • OI 1.9B
  • IPO Year
  • EWTX 2021
  • OI N/A
  • Fundamental
  • Price
  • EWTX $15.40
  • OI $12.20
  • Analyst Decision
  • EWTX Buy
  • OI Buy
  • Analyst Count
  • EWTX 10
  • OI 7
  • Target Price
  • EWTX $37.90
  • OI $16.14
  • AVG Volume (30 Days)
  • EWTX 875.0K
  • OI 1.2M
  • Earning Date
  • EWTX 11-06-2025
  • OI 11-04-2025
  • Dividend Yield
  • EWTX N/A
  • OI N/A
  • EPS Growth
  • EWTX N/A
  • OI N/A
  • EPS
  • EWTX N/A
  • OI N/A
  • Revenue
  • EWTX N/A
  • OI $6,482,000,000.00
  • Revenue This Year
  • EWTX N/A
  • OI $1.90
  • Revenue Next Year
  • EWTX N/A
  • OI $1.05
  • P/E Ratio
  • EWTX N/A
  • OI N/A
  • Revenue Growth
  • EWTX N/A
  • OI N/A
  • 52 Week Low
  • EWTX $10.60
  • OI $9.23
  • 52 Week High
  • EWTX $38.12
  • OI $16.04
  • Technical
  • Relative Strength Index (RSI)
  • EWTX 51.61
  • OI 44.97
  • Support Level
  • EWTX $14.88
  • OI $11.20
  • Resistance Level
  • EWTX $16.08
  • OI $12.38
  • Average True Range (ATR)
  • EWTX 0.85
  • OI 0.41
  • MACD
  • EWTX -0.04
  • OI 0.01
  • Stochastic Oscillator
  • EWTX 50.88
  • OI 46.28

About EWTX Edgewise Therapeutics Inc.

Edgewise Therapeutics Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of treatments for severe, rare muscle disorders. It is developing orally bioavailable, small molecule therapies for musculoskeletal diseases. The company's product candidates are Sevasemten and EDG-7500. Sevasemten is an orally administered small molecule designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy (Duchenne) and Becker muscular dystrophy (Becker). The company is currently studying Sevasemten in Phase 2 trials, which are being held in the U.S. and Israel and in certain countries in Europe and Australasia.

About OI O-I Glass Inc.

O-I Glass is the world's largest manufacturer of glass bottles; 70% of its revenue comes from outside the United States. O-I has a leading position in key markets such as Europe, North America, and Brazil. Beer is the primary end market for O-I's glass bottles, which are also used for wine, soda, spirits, condiments, and food. O-I is looking to maintain or expand its dominant positions in Europe, North America, and South America.

Share on Social Networks: